Compass Pathways PLC primarily operates in the pharmaceutical and healthcare industry. As a leading mental health care company, Compass Pathways is dedicated to developing innovative therapies and advancing treatment options for patients with mental health disorders. With its focus on psilocybin therapy, the company aims to address the significant unmet needs in mental health through research, development, and collaboration with healthcare professionals. Compass Pathways PLC is committed to improving patient outcomes and transforming mental healthcare by providing effective and safe solutions for individuals living with mental health conditions.

The main competitors of Compass Pathways PLC in the market include companies such as MindMed Inc., Cybin Inc., and Atai Life Sciences AG.

Compass Pathways PLC is a renowned mental healthcare company specializing in the research and development of psychedelic therapies. Founded in 2016, the company aims to address the significant unmet need for effective, innovative treatments for mental health conditions such as depression. With a focus on psilocybin therapy, Compass Pathways PLC actively conducts clinical trials and collaborates with world-leading research institutions to advance psychedelic-assisted therapy. By leveraging their expertise and strategic partnerships, Compass Pathways PLC strives to revolutionize mental health care and deliver transformative solutions to patients worldwide.

Compass Pathways PLC, a renowned mental healthcare company, has achieved several significant milestones. Firstly, the company successfully obtained FDA breakthrough therapy designation for their psilocybin therapy, affirming its potential to address treatment-resistant depression. Secondly, they initiated the ground-breaking clinical trial, COMPASS Pathways, investigating the efficacy of psilocybin-assisted therapy for depression. Moreover, Compass Pathways PLC received a USD 24.4 million grant from the European Union's Horizon 2020 program, further supporting their research efforts. Additionally, the company went public on the NASDAQ stock exchange, symbol CMPS, raising substantial capital to propel their pioneering work. These achievements highlight Compass Pathways PLC's commitment to advancing mental health treatments and their growing prominence in the field.

Compass Pathways PLC, a leading mental healthcare company, is primarily present in the United States, United Kingdom, and Europe. With a global presence and a mission to develop innovative therapies, Compass Pathways PLC has established itself as a prominent player in the mental health treatment market. The company is specifically focused on developing psilocybin therapy, a potential breakthrough treatment for depression and other mental health disorders. With its strategic presence in key regions, Compass Pathways PLC aims to shape the future of mental healthcare worldwide.

Compass Pathways PLC represents a strong commitment to advancing mental health treatment. The company's corporate philosophy revolves around using innovation and rigorous scientific research to address the unmet needs in mental health care. Compass Pathways PLC places a high value on patients' well-being and aims to revolutionize the treatment of challenging mental health conditions like treatment-resistant depression through their breakthrough therapy, psilocybin. By emphasizing safety, efficacy, and patient-centric care, Compass Pathways PLC aspires to empower individuals suffering from mental health disorders and improve their quality of life.

Analysts currently set an average price target of 19,84 USD for the Compass Pathways stock (median: 20,40 USD), implying +74,8 % versus the latest price. The consensus is based on 17 analyst ratings.

Compass Pathways Koersdoelstellingen analisten 2026

17 analysts currently rate the Compass Pathways stock: 15 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Compass Pathways to generate revenue of 2,14 Miljoen USD and earnings per share of -0,96 USD.

Compass Pathways Koersdoelstellingen analisten 2026

Converted at the current exchange rate, the Compass Pathways share trades at 9,84 EUR (11,35 USD).

The Compass Pathways share (CMPS) is listed on 4 stock exchanges, including: NASDAQ (CMPS), Frankfurt (5Y6.F), München (5Y6.MU), Düsseldorf (5Y6.DU).

Compass Pathways PLC is a company specializing in the development of therapeutic psychedelic products. The English company was founded in 2016 and is headquartered in London. The business model of Compass Pathways PLC involves the research and development of psychoactive substances that are intended to be used in the treatment of mental illnesses. The company focuses particularly on the development of psilocybin, a compound found in mushrooms that affects the central nervous system and is known to induce hallucinations and altered perceptions. Compass Pathways is currently active in two different areas: research and clinical development. In research, the company is working on identifying new compounds and developing new methods of administering them. The key areas of focus are effectiveness, safety, and tolerability. In the context of clinical development, Compass Pathways is engaged in testing the effectiveness and tolerability of its products in clinical trials in order to obtain market approval. One of Compass Pathways' main products is psilocybin, which is administered in the form of capsules. These are intended to be used particularly in the treatment of depression and anxiety disorders. The aim is to enable patients to have a new experience of themselves and their environment in order to establish long-term changes in thinking and behavior patterns. The company collaborates closely with various research institutions and partners to advance psychedelic research and increase acceptance of these therapeutic options. Compass Pathways is also already cooperating with online therapy providers to enable a wider use of therapy products. As a business model, Compass Pathways aims to develop innovative and effective therapeutic options to improve the quality of life for patients with mental illnesses. The company works closely with various stakeholders in the healthcare sector and emphasizes networking to increase the likelihood of success. Overall, Compass Pathways' business model is characterized by a high degree of innovation and a special focus on the needs of patients. The focus on psychedelic substances and their therapeutic use makes the company a pioneer in this novel program area.

De verwachte omzet van Compass Pathways bedraagt 2,14 Miljoen USD. Deze cijfers zijn gebaseerd op huidige financiële gegevens en weerspiegelen de bedrijfsresultaten van het bedrijf.

De verwachte winst van Compass Pathways bedraagt -89,58 Miljoen USD. De nettowinst weerspiegelt de rentabiliteit van het bedrijf na aftrek van alle kosten.

De koers-winstverhouding (P/E) van Compass Pathways bedraagt momenteel -11,86. De P/E-ratio vergelijkt de huidige aandeelkoers met de winst per aandeel en helpt beleggers de waardering van het Compass Pathways-aandeel in te schatten.

De koers-omzetverhouding (P/S) van Compass Pathways bedraagt momenteel 495,96. De P/S-ratio vergelijkt de marktkapitalisatie met de jaarlijkse opbrengsten en dient als waarderingsmaatstaf voor het Compass Pathways-aandeel.

De Eulerpool Kwaliteitsscore voor Compass Pathways is 2/10.

De ISIN van Compass Pathways is US20451W1018. De ISIN (International Securities Identification Number) is een wereldwijd unieke identificatie voor wertpapieren.

De WKN van Compass Pathways is A2QCDR. De WKN (Wertpapierkennnummer) is een zescijferig Duits identificatienummer voor wertpapieren.

Het tickersymbool van Compass Pathways is CMPS. Onder dit beurstickersymbool wordt het Compass Pathways-aandeel op de beurs verhandeld.

Compass Pathways betaalde de afgelopen 0 jaar elk jaar dividend.

Compass Pathways wordt toegewezen aan de sector 'Gezondheid'.

De dividenden van Compass Pathways worden in USD uitgekeerd.